Evolution of the Average Target: Lexicon Pharmaceuticals, Inc.

Evolution of the Target Price: Lexicon Pharmaceuticals, Inc.

Changes in Analyst Recommendations: Lexicon Pharmaceuticals, Inc.

1697f565a4177c92.b5XLm3zZJJl3Jww6v0PEEkVVp3nklTn_ZckSMaRHPUA.LPy8-E-rc8EAVn5dyjKWXw0tzB6HxWzNPfEhdessSCcs5KypNphwyCVdRQ~fa82062a3e9562e261e0afc53a5321ef
11-06 Relay Therapeutics, Inc. Appoint Board and Committee, Effective November 4, 2025 CI
25-03-05 Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2 MT
24-11-22 HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating MT
24-06-17 HC Wainwright Initiates Lexicon Pharmaceuticals With Buy Rating, $10 Price Target MT
24-04-30 Leerink Partners Starts Lexicon Pharmaceuticals With Outperform Rating, $5 Price Target MT
23-05-31 Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating MT
23-03-07 Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target MT
22-08-12 Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target MT
22-07-01 Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating MT
21-10-11 LEXICON PHARMACEUTICALS : Wedbush Suspended Coverage on Lexicon Pharmaceuticals MT
21-08-30 LEXICON PHARMACEUTICALS : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating MT
21-05-11 LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept MT
21-01-29 LEXICON PHARMACEUTICALS : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7 MT
21-01-29 LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2 MT
20-12-08 LEXICON PHARMACEUTICALS : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10 MT
20-11-18 LEXICON PHARMACEUTICALS : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold MT
20-11-03 LEXICON PHARMACEUTICALS : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+56.11%
+12.99%
+17.61%
+52.8%
+2.59%
+28.68%
+20.39%
+5.12%
-13.44%
-2.09%
Average +18.07%
Weighted average by Cap. +16.57%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.400USD
Average target price
3.856USD
Spread / Average Target
+60.67%
High Price Target
6.000USD
Spread / Highest target
+150.00%
Low Price Target
2.000USD
Spread / Lowest Target
-16.67%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Leerink Partners
HC Wainwright
Ladenburg Thalmann
Citigroup
Jefferies & Co.
Piper Sandler
Wedbush
J.P. Morgan Chase
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.400USD
Average target price
3.856USD
Spread / Average Target
+60.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock
  4. Consensus Lexicon Pharmaceuticals, Inc.